Names and pronunciation
(a-TOE-je-pant) Qulipta
PDF page 121
Loading InternPractice…
Drug reference
(a-TOE-je-pant) Qulipta
PDF page 121
Func. class.: Migraine agent
PDF page 121
Chem. class.: Calcitonin gene-related peptide
PDF page 121
ACTION: Centrally, CGRP is involved in transmis- sion through neurons and pain modula- tion in the brainstem
PDF page 121
USES: Migraine prevention
PDF page 121
CONTRAINDICATIONS A None Precautions: Breastfeeding, pregnancy, hepatic disease, CYP3A4 inhibitors, OATP inhibitors
PDF page 121
SIDE EFFECTS • CNS: Fatigue • GI: Nausea, constipation
PDF page 121
INTERACTIONS Dose modifications may be needed with CYP3A4 inhibitors or OATP inhibitors
PDF page 121
DOSAGE AND ROUTES • Adult: PO 10, 30, or 60 mg daily; if used with strong CYP3A4 inhibitor: 10 mg daily; strong and moderate CYP3A4 inducers: 30 mg or 60 mg daily; OATP inhibitors: 10 mg or 30 mg daily
PDF page 121
Available forms: Tablets 10, 30, 60 mg
PDF page 121
Administer: • Take without regard to food
PDF page 121
Assess: • Migraines: Identify severity, triggers, nausea, auras, and if this product lessens the number of migraines • Pregnancy/breastfeeding: May cause fetal harm, discontinue breastfeeding • Severe hepatic disease: Avoid use in patients with severe hepatic impairment
PDF page 121
Evaluate: • Therapeutic response: Prevention of migraine
PDF page 121
CLINICAL CONSIDERATIONS
PDF page 121
Patient and caregiver information: • Migraines: Teach patient to keep a record of number of migraines, triggers, character • Pregnancy/breastfeeding: Teach patient to report if pregnancy is planned or suspected or if breastfeeding • Interactions: Inform patients that this product may interact with some other drugs and that dosage modifications may be recommended when used with some other drugs. Advise patients to report to their health care provider the use of other Rx, OTC, herbals, grapefruit juice
PDF page 121
PHARMACOKINETICS Onset, duration unknown, peak 1-2 hr; half-life 11 hr
PDF page 121
• Adult: PO 10, 30, or 60 mg daily; if used with strong CYP3A4 inhibitor: 10 mg daily; strong and moderate CYP3A4 inducers: 30 mg or 60 mg daily; OATP inhibitors: 10 mg or 30 mg daily
PDF page 121